Role of metformin in patients with polycystic ovary syndrome: the state of the art.
Metformin, an insulin sensitizer widely used for the treatment of patients with type-2 diabetes mellitus (DM), was recently introduced in the clinical practice to treat women with polycystic ovary syndrome (PCOS). The aim of the current review was to evaluate the current role of metformin in the treatment of the PCOS-related disorders. The Authors analyze here the administration of metformin for treating the ovarian dysfunction due to PCOS, and show the evidences available in literature regarding its alternative uses.
Palomba
S
S
Department of Gynecology and Obstetrics, Magna Graecia University of Catanzaro, Catanzaro, Italy. stefanopalomba@tin.it
Falbo
A
A
Russo
T
T
Orio
F
F
Tollino
A
A
Zullo
F
F
D002996:Clomiphene / Q000008:administration & dosage / Q000627:therapeutic use; D015897:Comorbidity; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000453:epidemiology; D004359:Drug Therapy, Combination; D005260:Female; D005300:Fertility Agents, Female / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D015201:Meta-Analysis as Topic; D008687:Metformin / Q000627:therapeutic use*; D010053:Ovary / Q000503:physiopathology; D010062:Ovulation Induction; D011085:Polycystic Ovary Syndrome / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology; D011247:Pregnancy; D011256:Pregnancy Outcome; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors
D005300:Fertility Agents, Female; D007004:Hypoglycemic Agents; D002996:Clomiphene; D008687:Metformin